tetano
Editor, Senior Moderator
Antiviral Res. 2011 Feb 10. [Epub ahead of print]
A Single Intramuscular Injection of Neuraminidase inhibitor Peramivir Demonstrates Antiviral Activity against Novel Pandemic A/California/04/2009 (H1N1) Influenza Virus Infection in Mice.
Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS.
BioCryst Pharmaceuticals, Inc., Birmingham, AL, USA.
Abstract
New and emerging influenza virus strains, such as the pandemic influenza A (H1N1) virus require constant vigilance for antiviral drug sensitivity and resistance. Efficacy of intramuscularly (IM) administered neuraminidase (NA) inhibitor, peramivir, was evaluated in mice infected with recently isolated pandemic A/California/04/2009 (H1N1, swine origin, mouse adapted) influenza virus. A single IM injection of peramivir (four dose groups), given 1 hr prior to inoculation, significantly reduced weight loss (p<0.001) and mortality (p<0.05) in mice infected with LD(90) dose of pandemic A/California/04/2009 (H1N1) influenza virus compared to vehicle group. There was 20% survival in the vehicle-treated group, whereas in the peramivir-treated groups, survival increased in a dose-dependent manner with 60, 60, 90 and 100% survivors for the 1, 3, 10, and 30mg/kg doses, respectively. Weight loss on day 4 in the vehicle-treated group was 3.4 gm, and in the peramivir-treated groups was 2.1, 1.5, 1.8 and 1.8 gm for the 1, 3, 10 and 30mg/kg dose groups, respectively. In the treatment model, peramivir given 24hrs after infection as a single IM injection at 50mg/kg dose, showed significant protection against lethality and weight loss. There was 13% survival in the vehicle-treated group while in the peramivir-treated group at 24, 48, and 72hrs post infection, survival was 100, 40, and 50%, respectively. Survival in the oseltamivir groups (10mg/kg/d twice a day, orally for 5days) was 90, 30 and 20% at 24, 48 and 72hrs, respectively. These data demonstrate efficacy of parenterally administered peramivir against the recently isolated pandemic influenza virus in murine infection models.
Copyright ? 2011. Published by Elsevier B.V.
PMID: 21316393 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21316393
A Single Intramuscular Injection of Neuraminidase inhibitor Peramivir Demonstrates Antiviral Activity against Novel Pandemic A/California/04/2009 (H1N1) Influenza Virus Infection in Mice.
Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS.
BioCryst Pharmaceuticals, Inc., Birmingham, AL, USA.
Abstract
New and emerging influenza virus strains, such as the pandemic influenza A (H1N1) virus require constant vigilance for antiviral drug sensitivity and resistance. Efficacy of intramuscularly (IM) administered neuraminidase (NA) inhibitor, peramivir, was evaluated in mice infected with recently isolated pandemic A/California/04/2009 (H1N1, swine origin, mouse adapted) influenza virus. A single IM injection of peramivir (four dose groups), given 1 hr prior to inoculation, significantly reduced weight loss (p<0.001) and mortality (p<0.05) in mice infected with LD(90) dose of pandemic A/California/04/2009 (H1N1) influenza virus compared to vehicle group. There was 20% survival in the vehicle-treated group, whereas in the peramivir-treated groups, survival increased in a dose-dependent manner with 60, 60, 90 and 100% survivors for the 1, 3, 10, and 30mg/kg doses, respectively. Weight loss on day 4 in the vehicle-treated group was 3.4 gm, and in the peramivir-treated groups was 2.1, 1.5, 1.8 and 1.8 gm for the 1, 3, 10 and 30mg/kg dose groups, respectively. In the treatment model, peramivir given 24hrs after infection as a single IM injection at 50mg/kg dose, showed significant protection against lethality and weight loss. There was 13% survival in the vehicle-treated group while in the peramivir-treated group at 24, 48, and 72hrs post infection, survival was 100, 40, and 50%, respectively. Survival in the oseltamivir groups (10mg/kg/d twice a day, orally for 5days) was 90, 30 and 20% at 24, 48 and 72hrs, respectively. These data demonstrate efficacy of parenterally administered peramivir against the recently isolated pandemic influenza virus in murine infection models.
Copyright ? 2011. Published by Elsevier B.V.
PMID: 21316393 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21316393